Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Central nervous system manifestations in acute and chronic graft-versus-host disease.
Lambert N, Forte F, El Moussaoui M, Monseur J, Raus N, Polushin A, Michonneau D, Shultz C, Hogan WJ, Balaguer-Roselló A, Gil-Perotìn S, Brijs J, Chauvet P, Gavriilaki M, Carre M, Dulamea AO, Chalandon Y, Salmenniemi U, Duminuco A, Ram R, García-Cadenas I, Porto G, Nguyen S, Smallbone P, González-Vicent M, Santoro JD, Willems E, Baron F, Servais S, Beguin Y, Maquet P; CNS-GvHD Study Group. Lambert N, et al. Among authors: duminuco a. Brain. 2024 Oct 23:awae340. doi: 10.1093/brain/awae340. Online ahead of print. Brain. 2024. PMID: 39442000
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.
Duminuco A, Au Yeung J, Vaghela R, Virdee S, Woodley C, Asirvatham S, Curto-Garcia N, Sriskandarajah P, O'Sullivan J, de Lavallade H, Radia D, Kordasti S, Palumbo G, Harrison C, Harrington P. Duminuco A, et al. Hemasphere. 2024 Aug 8;8(8):e143. doi: 10.1002/hem3.143. eCollection 2024 Aug. Hemasphere. 2024. PMID: 39131900 Free PMC article. No abstract available.
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: duminuco a. Cancer. 2024 Jul 30. doi: 10.1002/cncr.35489. Online ahead of print. Cancer. 2024. PMID: 39078647
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.
Gozzo L, Leotta S, Romano GL, Vetro C, Duminuco A, Milone G, Cupri A, Palumbo FE, Brancati S, Ruscica R, Longo L, Vitale DC, Fiorenza G, Lombardo GE, Lazzara A, Di Raimondo F, Palumbo GA, Drago F. Gozzo L, et al. Among authors: duminuco a. J Clin Med. 2024 Jul 22;13(14):4273. doi: 10.3390/jcm13144273. J Clin Med. 2024. PMID: 39064314 Free PMC article.
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients.
Mangione R, Giallongo C, Duminuco A, La Spina E, Longhitano L, Giallongo S, Tibullo D, Lazzarino G, Saab MW, Sbriglione A, Palumbo GA, Graziani A, Alanazi AM, Di Pietro V, Tavazzi B, Amorini AM, Lazzarino G. Mangione R, et al. Among authors: duminuco a. Antioxidants (Basel). 2024 Apr 19;13(4):490. doi: 10.3390/antiox13040490. Antioxidants (Basel). 2024. PMID: 38671937 Free PMC article.
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey.
Duminuco A, Romano A, Ferrarini I, Santuccio G, Chiarenza A, Figuera A, Caruso LA, Motta G, Palumbo GA, Mogno C, Moioli A, Di Raimondo F, Visco C. Duminuco A, et al. Ann Hematol. 2024 Aug;103(8):3043-3052. doi: 10.1007/s00277-024-05752-6. Epub 2024 Apr 17. Ann Hematol. 2024. PMID: 38630129
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Leotta S, Markovic U, Duminuco A, Mulè A, Porretto F, Federico V, Gentile M, Pastore D, Nigro LL, Selleri C, Serio B, Calafiore V, Patti C, Mauro E, Vetro C, Maugeri C, Parisi M, Fiumara P, Parrinello L, Marino S, Scuderi G, Garibaldi B, Musso M, Renzo ND, Vigna E, Martino EA, Raimondo FD, Milone G. Leotta S, et al. Among authors: duminuco a. Ann Hematol. 2024 Sep;103(9):3701-3712. doi: 10.1007/s00277-024-05725-9. Epub 2024 Apr 13. Ann Hematol. 2024. PMID: 38609726
51 results